Jefferies Initiates Coverage on Haemonetics With Buy Rating
Jefferies has initiated coverage on Haemonetics Corporation with a Buy rating and a price target of $150.
Stocks · News reference
Haemonetics Corporation has received CE Mark certification for its VASCADE MVP XL venous vascular closure system, marking a regulatory milestone for the medical technology company.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has initiated coverage on Haemonetics Corporation with a Buy rating and a price target of $150.
Financial analysts at Citigroup and Barrington Research issued updated price targets and maintained positive ratings for Haemonetics Corporation on November 6, 2026.
Barrington Research has increased its price target for Haemonetics Corporation from $140 to $145 while maintaining an Outperform rating.
Haemonetics (NYSE:HAE) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Haemonetics Corporation released its financial results for the second quarter of fiscal year 2027, covering the period ended September 26, 2026.